Retour aux projets

14450.2;3 PFLS-LS

A robust CHO cell-based process platform for rapid manufacture of novel fully human bispecific monoclonal antibodies with importance for preclinical studies, immuno- and cancer therapies

Résumé

A robust CHO cell-based process platform for rapid manufacture of novel fully human bispecific monoclonal antibodies with importance for preclinical studies, immuno- and cancer therapies

Textes supplémentaires

Abstract

The project aims to establish a robust commercial-scale manufacturing platform for the kappa lambda body (¿Û¿Ü-body), a novel fully human bispecific antibody format. This new generation of biotherapeutics considerably extends the application fields of current classical monoclonal antibodies. In order to ensure process robustness and rapid production, a chemically defined minimal culture medium and single-use bioreactors are to be used. The 4 project partners will demonstrate the platform¡¿s suitability for one candidate ¿Û¿Ü-body, which will be correctly glycosylated and folded, with > 2.5 g L-1 of total antibody.

Participants

Regine Eibl

Kontaktperson

regine.eibl@zhaw.ch

Zürcher Hochschule für Angewandte W ZHAW Regine Eibl Campus Grüntal Dep. für Life Sciences & Facili 8820 Wädenswil ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-05-31
Date de fin
2015-03-09
Coûts totaux approuvés
CHF 352952.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T490 Biotechnology 100.0%